Abstract
Metabolic syndrome (MetS) and cardiovascular disease is rapidly evolving.To treat hypertension, drug-classes with different glucometabolic effects are used but they have the potential for adverse metabolic effects. An open-label prospective crossover study was conducted to compare the PPARγ( peroxisome proliferative activated receptor γ) modulating activity of olmesartan (10 mg/day) and telmisartan (20 mg/day) on stage 1 hypertension, metabolic parameters and cardiovascular risk using Framingham risk score based on lipid profile. Twenty patients were recruited for two months according to ATP III (adult treatment plan), specific criteria used for the diagnosis of MetS. Analyzed the blood pressure lowering effects of each drug on an interval of 2 weeks. Simultaneously measured metabolic parameters on first visit & on last follow up. Telmisartan and olmesartan showed the pleiotropic effect by lowering metabolic parameters. Telmisartan shows more significant reduction in metabolic parameters and a significant increase in HDL (high density lipoprotein) values. Both the drugs show an increase in cardiovascular risk percentage. Our results recommend a future research in the use of telmisartan and olmesartan in cardiovascular risk patients with MetS.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
